JP2010513224A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010513224A5 JP2010513224A5 JP2009524246A JP2009524246A JP2010513224A5 JP 2010513224 A5 JP2010513224 A5 JP 2010513224A5 JP 2009524246 A JP2009524246 A JP 2009524246A JP 2009524246 A JP2009524246 A JP 2009524246A JP 2010513224 A5 JP2010513224 A5 JP 2010513224A5
- Authority
- JP
- Japan
- Prior art keywords
- phenoxy
- propyl
- diphenylmethyl
- group
- substituents selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001424 substituent group Chemical group 0.000 description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 4
- VZKQWUSMUDKQQO-UHFFFAOYSA-N 2-[3-[3-(5-benzhydryl-2-oxopyridin-1-yl)propyl]phenoxy]acetic acid Chemical compound OC(=O)COC1=CC=CC(CCCN2C(C=CC(=C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=O)=C1 VZKQWUSMUDKQQO-UHFFFAOYSA-N 0.000 description 4
- -1 methylene -O - Chemical class 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- AROMICDCRVKJNE-UHFFFAOYSA-N 2-[4-[3-(5-benzhydryl-2-oxopyridin-1-yl)propyl]indol-1-yl]acetic acid Chemical compound C1=CC=C2N(CC(=O)O)C=CC2=C1CCCN(C(C=C1)=O)C=C1C(C=1C=CC=CC=1)C1=CC=CC=C1 AROMICDCRVKJNE-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000002993 cycloalkylene group Chemical group 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- KTSBJLUEVCOILP-NRFANRHFSA-N (2s)-2-[3-[3-(3-benzhydryl-6-oxopyridazin-1-yl)propyl]phenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=CC(CCCN2C(C=CC(=N2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=O)=C1 KTSBJLUEVCOILP-NRFANRHFSA-N 0.000 description 1
- NQUJSSMIVNNWJZ-NRFANRHFSA-N (2s)-2-[3-[3-(3-benzhydryl-6-oxopyridazin-1-yl)propylsulfanyl]phenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=CC(SCCCN2C(C=CC(=N2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=O)=C1 NQUJSSMIVNNWJZ-NRFANRHFSA-N 0.000 description 1
- ZVCYAALGOUJJSF-UHFFFAOYSA-N 4-[3-[2-(3-benzhydryl-6-oxopyridazin-1-yl)ethoxy]phenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=CC(OCCN2C(C=CC(=N2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=O)=C1 ZVCYAALGOUJJSF-UHFFFAOYSA-N 0.000 description 1
- PZGHUBPVYKMTOV-UHFFFAOYSA-N 4-[3-[2-(3-benzhydryl-6-oxopyridazin-1-yl)ethylsulfanyl]phenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=CC(SCCN2C(C=CC(=N2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=O)=C1 PZGHUBPVYKMTOV-UHFFFAOYSA-N 0.000 description 1
- DFWFRBMZNISVLY-UHFFFAOYSA-N 4-[3-[2-(5-benzhydryl-2-oxopyridin-1-yl)ethylsulfanyl]phenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=CC(SCCN2C(C=CC(=C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=O)=C1 DFWFRBMZNISVLY-UHFFFAOYSA-N 0.000 description 1
- SOLKEOGYJUBIEE-UHFFFAOYSA-N 4-[3-[3-(3-benzhydryl-6-oxo-4,5-dihydropyridazin-1-yl)propyl]phenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=CC(CCCN2C(CCC(=N2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=O)=C1 SOLKEOGYJUBIEE-UHFFFAOYSA-N 0.000 description 1
- VMMHBVUKRFYWDE-UHFFFAOYSA-N 4-[3-[3-(3-benzhydryl-6-oxopyridazin-1-yl)propyl]phenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=CC(CCCN2C(C=CC(=N2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=O)=C1 VMMHBVUKRFYWDE-UHFFFAOYSA-N 0.000 description 1
- ZFOMKUZFVBUCAJ-UHFFFAOYSA-N 4-[3-[3-(5-benzhydryl-2-oxopyridin-1-yl)propylsulfanyl]phenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=CC(SCCCN2C(C=CC(=C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=O)=C1 ZFOMKUZFVBUCAJ-UHFFFAOYSA-N 0.000 description 1
- ZSKWGHAKUVYLSD-UHFFFAOYSA-N 4-[3-[3-[3-[bis(4-fluorophenyl)methyl]-6-oxopyridazin-1-yl]propyl]-4-fluorophenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=C(F)C(CCCN2C(C=CC(=N2)C(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)=O)=C1 ZSKWGHAKUVYLSD-UHFFFAOYSA-N 0.000 description 1
- HZUXMWPXCOEQBS-UHFFFAOYSA-N 4-[3-[3-[3-[bis(4-fluorophenyl)methyl]-6-oxopyridazin-1-yl]propyl]phenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=CC(CCCN2C(C=CC(=N2)C(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)=O)=C1 HZUXMWPXCOEQBS-UHFFFAOYSA-N 0.000 description 1
- UZMUEHXLTUQZII-UHFFFAOYSA-N 4-[3-[3-[5-[bis(4-fluorophenyl)methyl]-2-oxopyridin-1-yl]propyl]-4-fluorophenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=C(F)C(CCCN2C(C=CC(=C2)C(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)=O)=C1 UZMUEHXLTUQZII-UHFFFAOYSA-N 0.000 description 1
- STLJKWYMPVPQBD-UHFFFAOYSA-N 4-[3-[3-[5-[bis(4-fluorophenyl)methyl]-2-oxopyridin-1-yl]propyl]phenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=CC(CCCN2C(C=CC(=C2)C(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)=O)=C1 STLJKWYMPVPQBD-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010065563 Eosinophilic bronchitis Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 102000009389 Prostaglandin D receptors Human genes 0.000 description 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87001406P | 2006-12-14 | 2006-12-14 | |
| US60/870,014 | 2006-12-14 | ||
| PCT/JP2007/074475 WO2008072784A1 (en) | 2006-12-14 | 2007-12-13 | Polycyclic acid compounds useful as crth2 antagonists and antiallergic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010513224A JP2010513224A (ja) | 2010-04-30 |
| JP2010513224A5 true JP2010513224A5 (enExample) | 2011-01-20 |
| JP5278318B2 JP5278318B2 (ja) | 2013-09-04 |
Family
ID=39322513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009524246A Expired - Fee Related JP5278318B2 (ja) | 2006-12-14 | 2007-12-13 | Ｃｒｔｈ２拮抗剤および抗アレルギー剤として有用な多環酸化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8273745B2 (enExample) |
| EP (1) | EP2094662B1 (enExample) |
| JP (1) | JP5278318B2 (enExample) |
| KR (1) | KR20090096690A (enExample) |
| CN (2) | CN101636386A (enExample) |
| AR (1) | AR064346A1 (enExample) |
| AT (1) | ATE553084T1 (enExample) |
| CA (1) | CA2672601A1 (enExample) |
| ES (1) | ES2383239T3 (enExample) |
| MX (1) | MX2009006312A (enExample) |
| PL (1) | PL2094662T3 (enExample) |
| PT (1) | PT2094662E (enExample) |
| TW (1) | TW200848036A (enExample) |
| WO (1) | WO2008072784A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2676173A1 (en) * | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
| EP2296653B1 (en) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| CA2761650C (en) | 2009-05-13 | 2015-05-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis c virus inhibitors |
| CA2805452C (en) | 2010-07-05 | 2018-07-31 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
| TW201331179A (zh) | 2011-12-21 | 2013-08-01 | Actelion Pharmaceuticals Ltd | 雜環衍生物及其作為前列腺素ｄ２受體調節劑之用途 |
| HK1208681A1 (en) * | 2012-06-12 | 2016-03-11 | Abbvie Inc. | Pyridinone and pyridazinone derivatives |
| EP2885307A1 (en) | 2012-07-05 | 2015-06-24 | Actelion Pharmaceuticals Ltd. | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
| US10093640B2 (en) | 2012-09-21 | 2018-10-09 | Vanderbilt University | Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| JP2016507496A (ja) * | 2012-12-21 | 2016-03-10 | ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． | ブロモドメイン阻害剤としての新規複素環式化合物 |
| KR102307566B1 (ko) | 2013-06-21 | 2021-10-05 | 제니쓰 에피제네틱스 리미티드 | 신규한 바이사이클릭 브로모도메인 억제제 |
| CN105473581B (zh) | 2013-06-21 | 2019-04-23 | 齐尼思表观遗传学有限公司 | 作为溴结构域抑制剂的新取代的双环化合物 |
| CA2919948C (en) | 2013-07-31 | 2020-07-21 | Zenith Epigenetics Corp. | Novel quinazolinones as bromodomain inhibitors |
| WO2015031608A1 (en) | 2013-08-28 | 2015-03-05 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
| US10533010B2 (en) | 2014-03-27 | 2020-01-14 | Vanderbilt University | Substituted indole Mcl-1 inhibitors |
| RU2692485C2 (ru) | 2014-04-02 | 2019-06-25 | Интермьюн, Инк. | Противофиброзные пиридиноны |
| US9949965B2 (en) | 2014-10-17 | 2018-04-24 | Vanderbilt University | Tricyclic indole Mcl-1 inhibitors and uses thereof |
| US10179125B2 (en) | 2014-12-01 | 2019-01-15 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| HK1245246A1 (zh) | 2014-12-01 | 2018-08-24 | 恒翼生物医药科技(上海)有限公司 | 作为溴域抑制剂的取代吡啶酮 |
| WO2016092375A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Corp. | Substituted heterocycles as bromodomain inhibitors |
| CN107406438B (zh) | 2014-12-17 | 2021-05-14 | 恒翼生物医药科技(上海)有限公司 | 溴结构域的抑制剂 |
| CN105353095B (zh) * | 2015-11-16 | 2017-10-20 | 华南农业大学 | 一种西地那非及其结构类似物的免疫检测方法 |
| WO2017104728A1 (ja) * | 2015-12-16 | 2017-06-22 | 国立大学法人東京大学 | 食物アレルギー治療薬 |
| WO2017126635A1 (ja) * | 2016-01-22 | 2017-07-27 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| JP7086395B2 (ja) | 2016-03-04 | 2022-06-20 | ヴァンダービルト ユニバーシティー | 置換インドールＭｃｌ－１阻害剤 |
| US11608320B2 (en) | 2020-02-02 | 2023-03-21 | Kuwait University | Oxazolidinone hydroxamic acid derivatives |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2185104A1 (en) | 1994-03-10 | 1995-09-14 | Kiyoshi Taniguchi | Naphthalene derivatives as prostaglandin 12 agonists |
| JPH10505596A (ja) * | 1994-09-10 | 1998-06-02 | ビーエーエスエフ アクチェンゲゼルシャフト | アルキルフェニルアセタート |
| AU691673B2 (en) * | 1994-11-14 | 1998-05-21 | Dow Agrosciences Llc | Pyridazinones and their use as fungicides |
| DE19514568A1 (de) * | 1995-04-20 | 1996-10-24 | Merck Patent Gmbh | Arylalkyl-pyridazinone |
| AU4537900A (en) | 1999-05-17 | 2000-12-05 | Agouron Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
| EP1368035A1 (en) * | 2001-02-12 | 2003-12-10 | MERCK PATENT GmbH | Use of type 4 phosphodiesterase inhibitors in myocardial diseases |
| JPWO2004002530A1 (ja) | 2002-06-26 | 2005-10-27 | 小野薬品工業株式会社 | 慢性疾患治療剤 |
| EP1553075B1 (en) | 2002-10-03 | 2013-08-14 | Ono Pharmaceutical Co., Ltd. | Lpa receptor antagonists |
| EP1758579A1 (en) * | 2004-05-29 | 2007-03-07 | 7TM Pharma A/S | Crth2 receptor ligands for medicinal uses |
| DE102005057924A1 (de) | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102006037478A1 (de) | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2-(Heterocyclylbenzyl)-pyridazinonderivate |
-
2007
- 2007-12-13 EP EP07859872A patent/EP2094662B1/en not_active Not-in-force
- 2007-12-13 PT PT07859872T patent/PT2094662E/pt unknown
- 2007-12-13 WO PCT/JP2007/074475 patent/WO2008072784A1/en not_active Ceased
- 2007-12-13 TW TW096147687A patent/TW200848036A/zh unknown
- 2007-12-13 US US12/518,280 patent/US8273745B2/en not_active Expired - Fee Related
- 2007-12-13 CN CN200780046458A patent/CN101636386A/zh active Pending
- 2007-12-13 CN CN2011102832598A patent/CN102442941A/zh active Pending
- 2007-12-13 CA CA002672601A patent/CA2672601A1/en not_active Abandoned
- 2007-12-13 JP JP2009524246A patent/JP5278318B2/ja not_active Expired - Fee Related
- 2007-12-13 KR KR1020097008871A patent/KR20090096690A/ko not_active Withdrawn
- 2007-12-13 ES ES07859872T patent/ES2383239T3/es active Active
- 2007-12-13 PL PL07859872T patent/PL2094662T3/pl unknown
- 2007-12-13 AR ARP070105614A patent/AR064346A1/es unknown
- 2007-12-13 AT AT07859872T patent/ATE553084T1/de active
- 2007-12-13 MX MX2009006312A patent/MX2009006312A/es active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018135343A5 (enExample) | ||
| JP2009539828A5 (enExample) | ||
| JP2009501198A5 (enExample) | ||
| JP2010503688A5 (enExample) | ||
| JP2010523476A5 (enExample) | ||
| JP2009543799A5 (enExample) | ||
| JP2010155827A5 (enExample) | ||
| JP2015512931A5 (enExample) | ||
| JP2013526520A5 (enExample) | ||
| JP2008516968A5 (enExample) | ||
| JP2006506425A5 (enExample) | ||
| RU2011147374A (ru) | Диамидные соединения, обладающие активностью антагониста мускаринового рецептора и активностью агониста в2 адренергического рецептора | |
| JP2011519854A5 (enExample) | ||
| NZ601794A (en) | Di - substituted pyridine derivatives as anticancers | |
| JP2009527501A5 (enExample) | ||
| ME02297B (me) | Jedinjenja koja imaju aktivnost antagonista muskarinskih receptora i agonist beta2 adrenergičnog receptora | |
| JP2012530758A5 (enExample) | ||
| JP2008543860A5 (enExample) | ||
| JP2004533450A5 (enExample) | ||
| JP2012526082A5 (enExample) | ||
| JP2013542980A5 (enExample) | ||
| JP2014505017A5 (enExample) | ||
| JP2007522162A5 (enExample) | ||
| JP2008517020A5 (enExample) | ||
| JP2007500222A5 (enExample) |